[시장보고서]세계의 경도 인지장애 시장 : 질환 유형, 연령, 적응증, 치료법, 지역별 예측(-2032년)

세계의 경도 인지장애 시장 : 질환 유형, 연령, 적응증, 치료법, 지역별 예측(-2032년)

Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

상품코드 : 1549989 해당 상품은 즉시 배송 가능합니다

리서치사 : Market Research Future

발행일 : 2024년 08월

페이지 정보 : 영문 153 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,331,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950

￦ 8,813,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250

￦ 10,738,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

샘플 요청 목록에 추가

경도 인지장애 시장 규모는 2023년 19억 4,000만 달러, 22024년 20억 5,000만 달러에서 예측 기간 중 5.95CAGR로 추이하며, 2032년에는 32억 5,000만 달러 규모로 성장할 것으로 예측됩니다.

경도 인지장애 시장의 주요 촉진요인은 세계에서 경도 인지장애의 유병률 증가와 경도 인지장애에 대한 인식이 높아지는 것입니다. 다약제 병용 및 동반 질환의 조절로 인해 치료 옵션이 복잡해져 세계 시장 성장이 둔화될 것으로 예상되지만, 경도 인지장애의 조기 진단에 대한 기술 개발은 수익성 높은 시장 전망을 가져올 것으로 예상됩니다.

지역별 인사이트

북미 시장은 2022년 42.60%로 가장 큰 시장 점유율을 차지할 것으로 예상되며, 예측 기간 중 4.97%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 약 13억 1,000만 달러 규모에 달할 것으로 예상됩니다. 아시아태평양은 예측 기간 중 6.91%의 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 북미의 경도인지장애 시장은 향후 견고한 성장세를 보일 것으로 예상됩니다. 의료 인프라에 대한 투자와 최신 의료 솔루션에 대한 인식이 높아지면서 시장 성장을 더욱 촉진할 것으로 예상됩니다. 기존 기업과 신규 진출기업은 더 나은 수술 결과에 대한 수요 증가에 대응하기 위해 개선된 기술을 활용하여 이러한 잠재력을 포착할 준비를 하고 있습니다.

유럽 시장은 기술 발전, 의료비 상승, 경도 인지장애에 대한 부담 증가로 인해 시장 점유율 2위를 차지하고 있습니다. 독일이 가장 큰 시장 점유율을 차지하고 있으며, 영국은 유럽에서 가장 빠른 성장을 보일 것으로 예상됩니다.

세계의 경도 인지장애 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이·예측, 각종 구분·지역별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

영문목차

Global Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032

Market Overview

The market size for mild cognitive impairment was estimated to be USD 1.94 billion in 2023. The global mild cognitive impairment industry is expected to expand from USD 2.05 billion in 2024 to USD 3.25 billion by 2032, with a compound annual growth rate (CAGR) of 5.95% during the forecast period (2024-2032).

The growing prevalence of mild cognitive impairment around the world, as well as increased awareness of mild cognitive impairment, are the primary drivers of the Mild Cognitive Impairment Market. However, polypharmacy and controlling comorbidities complicate treatment options, which is projected to slow worldwide market growth. Nonetheless, technological developments in the early diagnosis of MCI around the world are expected to provide profitable market prospects. The rising global prevalence of moderate cognitive impairment (MCI) is a primary driver of the global MCI treatment industry.

Marketing Segmentation

Mild Cognitive Impairment Market Segmentation by Disease Type, Amnestic MCI, and Non-Amnestic MCI.

The mild cognitive impairment market segmentation by age comprises child, adult, and geriatric.

The Mild Cognitive Impairment Market has been classified according to indication: Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others.

The Mild Cognitive Impairment Market has been divided into two segments: medicine and therapy.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American mild cognitive impairment market had the greatest market share of 42.60% in 2022 and is expected to reach roughly USD 01.31 billion by 2032, growing at a 4.97% CAGR over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 6.91% over the forecast period. The North American mild cognitive impairment market is expected to increase steadily in the future. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.

Europe's mild cognitive impairment market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increased burden of mild cognitive impairment. Furthermore, the German mild cognitive impairment market is expected to have the biggest market share, with the UK mild cognitive impairment market forecast to be the fastest expanding market in Europe.

The Asia-Pacific mild cognitive impairment market is predicted to develop the fastest from 2024 to 2032, owing to a large patient population, an increasing number of mild cognitive cases, and favorable regulatory regulations. Furthermore, prominent companies in the mild cognitive impairment market are aggressively expanding into this region, propelling the regional market forward. Furthermore, China's mild cognitive impairment market had the greatest market share, while India's mild cognitive impairment market is expected to be the fastest expanding in the Asia-Pacific region.

Major Players

Key players in the mild cognitive impairment market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd. (Japan), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Taj Pharmaceuticals Limited (India).

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELLING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Increasing burden of Mild cognitive impairment across the globe
- 4.2.2 Rising awareness associated with mild cognitive impairment
4.3 RESTRAINTS
- 4.3.1 Polypharmacy and managing comorbidities complicate treatment strategies
4.4 OPPORTUNITY
- 4.4.1 Technological advancements for early diagnosis of MCI

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL MILD COGNITIVE IMPAIRMENT MARKET

6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE

6.1 OVERVIEW
6.2 AMNESTIC MCI
6.3 NON-AMNESTIC MCI

7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE

7.1 OVERVIEW
7.2 CHILD
7.3 ADULT
7.4 GERIATRIC

8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION

8.1 OVERVIEW
8.2 LEWY BODY DEMENTIA
8.3 PARKINSON'S DISEASE DEMENTIA
8.4 ALZHEIMER'S DISEASE
8.5 VASCULAR DEMENTIA
8.6 OTHERS

9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT

9.1 OVERVIEW
9.2 MEDICATION
- 9.2.1 Cholinesterase Inhibitors
- 9.2.2 Benzodiazepines
- 9.2.3 Glutamate Inhibitors
- 9.2.4 Antihistamines
- 9.2.5 Mao Inhibitors
- 9.2.6 Proton Pump Inhibitors
- 9.2.7 Others
9.3 THERAPY
- 9.3.1 Cognitive Stimulation Therapy
- 9.3.2 Cognitive Behavioural Therapy (CBT)

10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 us
- 10.2.2 canada
10.3 EUROPE
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 UK
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 South Korea
- 10.4.5 AUSTRALIA
- 10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
- 10.5.1 Middle East & Africa
- 10.5.2 Latin America

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 product launch / Product approval

12 COMPANY PROFILES

12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 productS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 PFIZER INC
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 productS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 NOVARTIS AG
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 productS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 BIOGEN
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 EISAI CO., LTD.
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 AUROBINDO PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 TAJ PHARMACEUTICALS LTD.
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

한글목차

목차

제1장 개요

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

제5장 시장 요인 분석

제6장 세계의 경도 인지장애 시장 : 질환 유형별

제7장 세계의 경도 인지장애 시장 : 연령별

제8장 세계의 경도 인지장애 시장 : 적응증별

제9장 세계의 경도 인지장애 시장 : 치료별

제10장 세계의 경도 인지장애 시장 : 지역별

제11장 경쟁 구도

제12장 기업 개요

제13장 데이터 인용